--- title: "Sagimet Biosciences | 8-K: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286091063.md" datetime: "2026-05-12T11:37:26.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286091063.md) - [en](https://longbridge.com/en/news/286091063.md) - [zh-HK](https://longbridge.com/zh-HK/news/286091063.md) --- # Sagimet Biosciences | 8-K: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.33, beating the estimate of USD -0.3588. EBIT: As of FY2026 Q1, the actual value is USD -12.78 M. ### Operational Metrics Sagimet Biosciences Inc. reported a net loss of - $10.7 million for the first quarter of 2026, improving from a net loss of - $18.2 million for the first quarter of 2025. The loss from operations was - $11.7 million for the first quarter of 2026, an improvement compared to - $19.9 million for the same period in 2025. Total operating expenses decreased to $11.7 million for the first quarter of 2026 from $19.9 million for the first quarter of 2025. Research and development expense for the first quarter of 2026 was $7.0 million, a decrease from $15.3 million for the first quarter of 2025. General and administrative expense was $4.7 million for the first quarter of 2026, slightly up from $4.5 million for the first quarter of 2025. Total other income was $1.1 million for the first quarter of 2026, down from $1.7 million for the first quarter of 2025. Net loss per share, basic and diluted, was - $0.33 for the first quarter of 2026, an improvement from - $0.56 for the first quarter of 2025. Weighted-average shares outstanding, basic and diluted, were 32,559,704 for the first quarter of 2026, compared to 32,195,345 for the first quarter of 2025. The net unrealized loss on marketable securities was - $0.1 million for both the first quarter of 2026 and the first quarter of 2025. Total comprehensive loss was - $10.8 million for the first quarter of 2026, an improvement from - $18.3 million for the first quarter of 2025. ### Balance Sheet Highlights Cash, cash equivalents and marketable securities totaled $104.5 million as of March 31, 2026, decreasing from $113.1 million as of December 31, 2025. Total assets were $107.8 million as of March 31, 2026, down from $116.5 million as of December 31, 2025. Current liabilities were $5.3 million as of March 31, 2026, compared to $5.1 million as of December 31, 2025. Stockholders’ equity was $102.5 million as of March 31, 2026, a decrease from $111.4 million as of December 31, 2025. ### Unique Financial Metrics Sagimet Biosciences Inc. secured equity financing with gross proceeds of $175.0 million in April 2026 through an underwritten offering of 29,166,700 shares of its Series A common stock at $6.00 per share. ### Outlook / Guidance Sagimet Biosciences Inc. anticipates that its existing cash, cash equivalents, and proceeds from the recent offering will fund its acne programs through 2028, including the data readout of the planned denifanstat Phase 3 clinical trial. The company plans to initiate a Phase 3 clinical trial of denifanstat for moderate to severe acne patients in the U.S. in the second half of 2026, subject to IND clearance. Additionally, following the completion of its Phase 1 clinical trial, Sagimet Biosciences Inc. aims to initiate a Phase 2 clinical trial for TVB-3567 in moderate to severe acne patients in the second half of 2026, pending consultation with regulatory authorities. ### Related Stocks - [SGMT.US](https://longbridge.com/en/quote/SGMT.US.md) ## Related News & Research - [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Yatra Online, Inc. to Host Fourth Quarter and Full Year 2026 Financial Results Call on May 25, 2026 | YTRA Stock News](https://longbridge.com/en/news/287242169.md) - [Endeavour Announces Results of Annual General Meeting 2026 | EDVMF Stock News](https://longbridge.com/en/news/287245296.md)